Lunit
Edit

Lunit

https://www.lunit.io/
Last activity: 08.09.2026
Active
Categories: AIBiomarkersDeepLearningDiagnosticsHealthcareMedicalImagingOncologyPathology
인류의 난제, 암. 루닛은 인공지능 기술로 암을 정복합니다.
암을 조기에 진단하고 항암제 효과를 예측하는 솔루션을 만듭니다.
Followers
711
Followers
5.55K
Website visits
40.2K /mo.
Mentions
154
Location: South Korea
Employees: 201-500
Total raised: $237M
Founded date: 2013

Investors 7

Funding Rounds 3

DateSeriesAmountInvestors
16.11.2023-$150M-
26.11.2021Pre-IPO$61M-
22.07.2021Series C$26M-

Mentions in press and media 154

DateTitleDescription
08.09.2026Lunit Unveils New AI-Powered Tumor Microenvironment Insights in Lung Cancer at WCLC 2026Three studies explore the relationship between tumor microenvironment, genomic alterations, and treatment response in non-small cell lung cancer using AI-based analysis SEOUL, South Korea, Sept. 8, 2026 /PRNewswire/ -- Lunit (KRX:328130), a...
08.07.2026AI in Medical Imaging Market to Reach $4.54 Billion by 2029The global artificial intelligence (AI) in medical imaging market is projected to grow from USD 1.65 billion in 2024 to USD 4.54 billion by 2029, at a robust CAGR of 22.4% during the forecast period. This strong growth is fueled by increasi...
22.05.2026Lunit Highlights AI-Powered IHC and Tumor Microenvironment Research at ASCO 2026At ASCO 2026, Lunit will present precision patient stratification and biomarker-driven oncology research through AI-powered HER2/IHC biomarker quantification and spatial tumor microenvironment analysis. SEOUL, South Korea, May 22, 2026 /PRN...
18.04.2026Lunit to Present Six AI Studies at AACR 2026 Highlighting Advances in Precision Oncology and Real-World Clinical ApplicationLunit's AACR 2026 presentations showed how AI-driven biomarkers can improve the efficiency of clinical workflows, uncover spatial features of the tumor microenvironment not captured by conventional methods, and enable integrated analysis to...
16.04.2026Lunit Surpasses 330+ Sites and 1M Annual Screenings as Breast Imaging AI Moves into Clinical PracticeLunit highlights enterprise AI adoption and FDA-cleared advancements at SBI 2026 SEOUL, South Korea, April 16, 2026 /PRNewswire/ -- At the Society of Breast Imaging (SBI) Annual Symposium, Lunit (KRX:328130), a leading provider of AI for ca...
04.03.2026Lunit to Be Featured in 21 AI Imaging Studies on Breast Cancer and Lung Disease at ECR 202613 oral presentations included, reaffirming the clinical value of AI-based medical image analysis Highlighting key topics such as early risk stratification based on AI abnormality scores and interval cancer classification SEOUL, South Korea...
04.03.2026Harrison.ai Continues to Grow Open Platform Ecosystem, Welcomes Four New AI PartnersFollowing the launch of its Open Platform last year, Harrison.ai today announced that four additional AI companies — AIRAmed, Koios Medical, Lunit and Nanox AI — would join the Harrison.ai Open Platform. This expansion reflects the platform...
15.12.2025Lunit Announces Collaboration with Daiichi Sankyo to Advance AI-Driven Biomarker Discovery and Translational Oncology ResearchCollaboration to leverage Lunit SCOPE IO ® and SCOPE universal IHC® (uIHC) digital pathology products in two Daiichi Sankyo oncology research and development programs SEOUL, South Korea, Dec. 15, 2025 /PRNewswire/ -- Lunit (KRX:328130), a l...
15.12.2025Lunit and Daiichi Sankyo Partner to Accelerate Cancer Biomarker Discovery with AIWhat You Should Know: – Lunit has announced a collaboration with pharmaceutical giant Daiichi Sankyo to integrate its AI-powered Lunit SCOPE digital pathology products into two of Daiichi Sankyo’s oncology pipeline programs. – The partnersh...
08.12.2025Lunit Submits 510(k) Application for Image-Based Breast Cancer Risk Prediction ModelSubmission marks a key regulatory milestone toward bringing SEER-calibrated, imaging-based risk assessment to U.S. screening programs SEOUL, South Korea, Dec. 8, 2025 /PRNewswire/ -- Lunit (KRX:328130), a leading provider of AI for cancer d...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In